Study # IOV-GM1-201

A Phase I/II, Open-Label Study of PD-1 Knockout Tumor Infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III/IV Non-Small Cell Lung Cancer

Study Status:

Enrolling

Treatment Agent:

IOV-4001

Description

Short Title: IOV-GM1-201

This study is the first-in-human study of IOV-4001, a genetically modified autologous tumor- infiltrating lymphocytes (TIL) product. IOV-4001 is expected to have antitumor activity through its capacity to directly target and kill tumor cells in a manner that is similar to non-genome-edited TIL, but with the potential for enhanced antitumor activity due to disruption of PDCD1, the gene for programmed cell death protein-1 (PD-1).

Resources and Links

National Clinical Trial Identified Number: NCT05361174

Information and next steps

Disease:

  • Unresectable Melanoma,
  • Metastatic Melanoma,
  • Stage III Non-small Cell Lung Cancer,
  • Stage IV Non-small Cell Lung Cancer

Study Phase:

I/II

Physician Name:

Department:

Ask a Question